gene editing
Vertex Pharmaceuticals, CRISPR Therapeutics' Gene-Editing Therapy Nabs UK Conditional Authorization
The decision makes the SCD and TDT treatment the first CRISPR-based therapy to receive marketing authorization in the world, the firms said.
The expert committee's positive reaction to the submitted data bodes well for what could be the first marketed CRISPR gene-editing therapy in the US.
Eli Lilly Scoops Up Beam's Opt-in Rights to Verve's Base-Editing Cardiovascular Genetic Medicines
Lilly will pay Beam $200 million upfront and make an equity investment for opt-in rights to Verve's programs targeting PCSK9, ANGPTL3, and an undisclosed target.
Healiva, C4U Join Forces to Develop CRISPR-Cas3 Drugs for Rare Skin Conditions
The strategic alliance will bring together Healiva's experience developing wound therapeutics with C4U's gene-editing platform for manufacturing.
Verve Therapeutics to Kick Off US Trial for Base-Editing Therapy After FDA Lifts Hold, Clears IND
The FDA had placed the firm's IND application for VERVE-101 on hold due to questions regarding germline editing and off-target effects.
Jun 18, 2020
May 30, 2019